These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 32366856)

  • 21. Anlotinib combined with the PD-L1 blockade exerts the potent anti-tumor immunity in renal cancer treatment.
    Li J; Cao P; Chen Y; Wang J; Sun X; Chen R; Wang G; Hou J
    Exp Cell Res; 2022 Aug; 417(1):113197. PubMed ID: 35568074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of the combination of sintilimab and chemotherapy on the tumor and paratumor PD-L1, IDO, TIM-3, FOXP3+ and CD8 expressions in patients with advanced esophageal squamous cell carcinoma.
    Zhang S; Cai H; Huang J; Wang G
    Thorac Cancer; 2022 Dec; 13(23):3284-3294. PubMed ID: 36288460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer.
    Zhu Y; Li M; Mu D; Kong L; Zhang J; Zhao F; Li Z; Liu X; Bo C; Yu J
    Oncotarget; 2016 Nov; 7(44):71455-71465. PubMed ID: 27683115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
    Gao Y; Yang J; Cai Y; Fu S; Zhang N; Fu X; Li L
    Int J Cancer; 2018 Aug; 143(4):931-943. PubMed ID: 29516506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
    Yoshimura K; Inoue Y; Tsuchiya K; Karayama M; Yamada H; Iwashita Y; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Lung Cancer; 2020 Mar; 141():21-31. PubMed ID: 31931443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
    Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
    Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expressions of Immune Negative Regulator FoxP3+Treg and PD-L1 Protein in the Immune Microenvironment of Cervical Lesion.
    Ma Q; Zhao M; Wei X; Zhao J; Yang T; Zhang Q; Wang K; Yang X
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Feb; 39(1):128-132. PubMed ID: 28270295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis.
    Ahn J; Bishop JA; Roden RBS; Allen CT; Best SRA
    Laryngoscope; 2018 Jan; 128(1):E27-E32. PubMed ID: 28940446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Immunomodulation in the tumor microenvironment: Therapeutic potential of combined inhibition of tumor hypoxia and PD-1/ PD-L1].
    Svajda L; Cserepes M; Hegyi B; Niczky T; Tóvári J
    Magy Onkol; 2024 Jul; 68(2):126-135. PubMed ID: 39013086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment.
    Li H; You J; Wei Y; Zheng L; Yang J; Xu J; Li Y; Li Z; Yang X; Yi C
    Phytomedicine; 2024 Jan; 123():155189. PubMed ID: 37984124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemokine C-C motif ligand 21 synergized with programmed death-ligand 1 blockade restrains tumor growth.
    Chen Q; Yin H; Pu N; Zhang J; Zhao G; Lou W; Wu W
    Cancer Sci; 2021 Nov; 112(11):4457-4469. PubMed ID: 34402138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
    Imai D; Yoshizumi T; Okano S; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Soejima Y; Aishima S; Oda Y; Maehara Y
    Cancer Med; 2017 Jul; 6(7):1614-1626. PubMed ID: 28602029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Curcumol inhibits the expression of programmed cell death-ligand 1 through crosstalk between hypoxia-inducible factor-1α and STAT3 (T705) signaling pathways in hepatic cancer.
    Zuo HX; Jin Y; Wang Z; Li MY; Zhang ZH; Wang JY; Xing Y; Ri MH; Jin CH; Xu GH; Piao LX; Ma J; Jin X
    J Ethnopharmacol; 2020 Jul; 257():112835. PubMed ID: 32278762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-L1 expression and infiltration by CD4
    Lee HJ; Shin DH; Lee YJ; Lee SJ; Hwang CS; Kim A; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Park SW
    Histopathology; 2020 Apr; 76(5):714-721. PubMed ID: 31841221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma.
    Jiang F; Yu W; Zeng F; Cheng G; Xu J; Yang S; Shui Y; Wu D; Yu XF; Wei Q
    BMC Cancer; 2019 May; 19(1):503. PubMed ID: 31138162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1+ dendritic cells in the tumor microenvironment correlate with good prognosis and CD8+ T cell infiltration in colon cancer.
    Miller TJ; Anyaegbu CC; Lee-Pullen TF; Spalding LJ; Platell CF; McCoy MJ
    Cancer Sci; 2021 Mar; 112(3):1173-1183. PubMed ID: 33345422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
    Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
    Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
    Berghoff AS; Ricken G; Wilhelm D; Rajky O; Widhalm G; Dieckmann K; Birner P; Bartsch R; Preusser M
    J Neurooncol; 2016 Oct; 130(1):19-29. PubMed ID: 27436101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.
    Tanegashima T; Togashi Y; Azuma K; Kawahara A; Ideguchi K; Sugiyama D; Kinoshita F; Akiba J; Kashiwagi E; Takeuchi A; Irie T; Tatsugami K; Hoshino T; Eto M; Nishikawa H
    Clin Cancer Res; 2019 Aug; 25(15):4808-4819. PubMed ID: 31076547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma.
    London NR; Rooper LM; Bishop JA; Xu H; Bernhardt LJ; Ishii M; Hann CL; Taube JM; Izumchenko E; Gaykalova DA; Gallia GL
    World Neurosurg; 2020 Mar; 135():e187-e193. PubMed ID: 31785431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.